AbbVie (ABBV) Tops Q2 EPS by 6c; Boosts FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain
July 29, 2016 11:54 AM EDTBMO Capital affirms AbbVie (NYSE: ABBV) at Market Perform with a price target of $66 following Q2 results out earlier Friday.
Analyst Alex Arfaei commented, revenue was 3.7% above consensus, driven by higher sales of Humira and Imbruvica, while OPEX was... More
AbbVie (ABBV) Initiates Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory
July 28, 2016 5:32 PM EDTAbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome... More
